Risk Scores for Death in Patients with Cancer-related Venous Thromboembolism: Still a Long Road Ahead

Daniele Pastori; Giancarlo Agnelli

doi:10.1055/s-0041-1727244

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2021; 121(06): 700-702
DOI: 10.1055/s-0041-1727244

Invited Editorial Focus

Risk Scores for Death in Patients with Cancer-related Venous Thromboembolism: Still a Long Road Ahead

Autor*innen

Daniele Pastori

¹Emergency Medicine Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
Giancarlo Agnelli

²Internal Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia, Italy

Abstract

Volltext

Referenzen

References
1 Spirk D, Sebastian T, Barco S. et al. Clinical outcomes of incidental venous thromboembolism in cancer and noncancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Thromb Haemost 2021; 121 (05) 641-649
2 Giustozzi M, Curcio A, Weijs B. et al. Variation in the association between antineoplastic therapies and venous thromboembolism in patients with active cancer. Thromb Haemost 2020; 120 (05) 847-856
3 Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost 2017; 117 (02) 219-230
4 Konstantinides SV, Meyer G, Becattini C. et al. ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
5 Lyman GH, Carrier M, Ay C. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5 (04) 927-974
6 Giustozzi M, Agnelli G, Del Toro-Cervera J. et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (07) 1128-1136
7 Cavallari I, Verolino G, Romano S, Patti G. Efficacy and safety of nonvitamin K oral anticoagulants in patients with atrial fibrillation and cancer: a study-level meta-analysis. Thromb Haemost 2020; 120 (02) 314-321
8 Ageno W, Vedovati MC, Cohen A. et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio Study. Thromb Haemost 2021; 121 (05) 616-624
9 Cohen A, Keshishian A, Lee T. et al. Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis. Thromb Haemost 2021; 121 (03) 383-395
10 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
11 Carmona-Bayonas A, Jimenez-Fonseca P, Garrido M. et al. multistate models: accurate and dynamic methods to improve predictions of thrombotic risk in patients with cancer. Thromb Haemost 2019; 119 (11) 1849-1859
12 Li X, Hu Y, Lin P. et al. Comparison of different clinical prognostic scores in patients with pulmonary embolism and active cancer. Thromb Haemost 2021;
13 Pastori D, Marang A, Bisson A. et al. Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study. Cancer 2021;
14 Aujesky D, Obrosky DS, Stone RA. et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172 (08) 1041-1046
15 Zondag W, Mos IC, Creemers-Schild D. et al; Hestia Study Investigators. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011; 9 (08) 1500-1507
16 Esteve-Pastor MA, Roldán V, Rivera-Caravaca JM, Ramírez-Macías I, Lip GYH, Marín F. The use of biomarkers in clinical management guidelines: a critical appraisal. Thromb Haemost 2019; 119 (12) 1901-1919
17 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
18 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
19 McBane II RD, Wysokinski WE, Le-Rademacher JG. et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020; 18 (02) 411-421
20 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
21 Agnelli G, Becattini C, Bauersachs R. et al; Caravaggio Study Investigators. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio Study. Thromb Haemost 2018; 118 (09) 1668-1678
22 Kline JA, Roy PM, Than MP. et al. Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: the POMPE-C tool. Thromb Res 2012; 129 (05) e194-e199
23 den Exter PL, Gómez V, Jiménez D. et al; Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) Investigators. A clinical prognostic model for the identification of low-risk patients with acute symptomatic pulmonary embolism and active cancer. Chest 2013; 143 (01) 138-145